Trending Alert: These 5 Companies Are Trending Now

Tickers Inside Powered by [FinancialMarketMovers.com]( Good Morning! Below is a list of 5 stocks that are trending with positive investor sentiment, news headlines, and buy ratings from top Wall Street analysts. Our editors are keeping an eye on these stocks and adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [Is Gold Really Boring?]( [See why this could be a huge untapped gold investing opportunity.]( --------------------------------------------------------------- [Apellis Pharmaceuticals, APLS]( Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases. Phil Nadeau analyst at TD Cowen reiterated coverage on [Apellis Pharmaceuticals (APLS)](in the Healthcare sector with a Buy rating and has set a price target of n/a. Our data shows [Apellis Pharmaceuticals]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $72.00. In addition, TradingView issued a Strong Buy rating for [APLS]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on APLS, please click here >>]( [Ionis Pharmaceuticals, IONS]( Summary: Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases. Jason Gerberry analyst at Bank of America Securities reiterated coverage on [Ionis Pharmaceuticals (IONS)](in the Healthcare sector with a Buy rating and has set a price target of $62. Our data shows [Ionis Pharmaceuticals]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $54.40. In addition, TradingView issued a Buy rating for [IONS]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on IONS, please click here >>]( --------------------------------------------------------------- Sponsor [Bezos and Gates Invest in Search for Tech's Best-Kept Secret]( who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible. [Investor Alert: Discover a company flying-under-the-radar at the forefront of this megatrend.]( --------------------------------------------------------------- [Morgan Stanley, MS]( Summary: Morgan Stanley, being the leading financial services holding company, serves corporations, governments, FIs & individuals world wide. It has 3 business units. The Institutional Securities unit includes capital raising, financial advisory services on mergers & acquisitions, restructurings, real estate & project finance, corporate lending, sales, trading, financing & market-making activities in equity & fixed income securities & related products. The Wealth Management unit provides brokerage & investment advisory services on various investment alternatives, financial & wealth planning services, annuity & other insurance products, credit & other lending products, cash management & retirement services and trust & fiduciary services and engages in fixed income principal trading. The Investment Management unit provides global asset management products & services in equity, fixed income, alternative investments in hedge funds & funds of funds and merchant banking i.e. real estate, private equity & infrastructure. Saul Martinez analyst at HSBC reiterated coverage on [Morgan Stanley (MS)](in the Financial sector with a Hold rating and has set a price target of $96. Our data shows [Morgan Stanley]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $104.80. In addition, TradingView issued a Buy rating for [MS]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on MS, please click here >>]( [Unity Software, U]( Summary: Unity Software Inc. provides platform for creating and operating interactive, real-time 3D content. The company platform provides set of software solutions to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles and augmented and virtual reality devices. Unity Software Inc. is based in San Francisco, United States. Dylan Becker analyst at William Blair reiterated coverage on [Unity Software (U)](in the Technology sector with a Buy rating and has set a price target of n/a. Our data shows [Unity Software]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $39.00. In addition, TradingView issued a Neutral rating for [U]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on U, please click here >>]( --------------------------------------------------------------- Sponsor [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Prothena, PRTA]( Summary: Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A'.'Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements. Jason Butler analyst at JMP Securities reiterated coverage on [Prothena (PRTA)](in the Healthcare sector with a Buy rating and has set a price target of $81. Our data shows [Prothena]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $91.20. In addition, TradingView issued a Strong Sell rating for [PRTA]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on PRTA, please click here >>]( --------------------------------------------------------------- Sponsor [The Strategic Gold Play You Haven't Heard About]( recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. [Get the full story on this overlooked gold investment strategy here.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [FinancialMarketMovers.com]( --------------------------------------------------------------- Sponsor [Breaking: Uncle Sam Must Secure "The Seeds of Technology"]( Earth Elements are a group of metals crucial for semiconductor chips, renewable energy, electric vehicles, and MUCH more. The problem is China accounts for 70% of global mine production of them. For the U.S. and Canada, it has become a matter of national security. [Learn more about this mega trend and one company hoping to meet demand.]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( FinancialMarketMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( This is part of your free subscription to FinancialMarketMovers. FinancialMarketMovers.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123